Peter Hellemans
Beerse, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies.
Journal: Cancer immunology, immunotherapy : CII
Published: March 02, 2026
A Phase 1, Open-Label, Single-Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor.
Journal: Clinical pharmacology in drug development
Published: October 17, 2025
Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study.
Journal: Clinical lung cancer
Published: October 10, 2025
Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype.
Journal: Clinical drug investigation
Published: June 27, 2025
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
Journal: Clinical pharmacokinetics
Published: December 14, 2023
Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: December 14, 2023
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.
Journal: Leukemia & lymphoma
Published: January 03, 2023
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: October 18, 2022
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
Journal: Pharmacology research & perspectives
Published: May 11, 2020
Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer.
Journal: Clinical pharmacokinetics
Published: April 28, 2020
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
Journal: Haematologica
Published: November 26, 2019
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 31, 2019
Last Updated: 09/26/2026